Vermillion to Present at the 26th Annual ROTH Conference on March 11, 2014
AUSTIN, Texas, March 3, 2014
AUSTIN, Texas, March 3, 2014 /PRNewswire/ --Vermillion, Inc. (NASDAQ: VRML),
a multivariate diagnostics company focused on gynecologic cancers and women's
health, has been invited to present at ROTH Capital Partners 26th Annual
Conference being held March 10-12, 2014, at the Ritz-Carlton in Dana Point,
President and CEO of Vermillion, Thomas McLain, is scheduled to present on
Tuesday, March 11, 2014, at 3:30 p.m. Pacific time, with one-on-one meetings
held throughout the day. He will be joined by Eric Schoen, the company's vice
president of finance and chief accounting officer. Management will discuss the
company's initiatives to drive market adoption of OVA1®, as well as plans to
expand its patient base and launch a next-generation diagnostic test.
For more information about the conference or to schedule a one-on-one meeting
with Vermillion management, please contact your ROTH representative at
1-800-933-6830 or via e-mail at firstname.lastname@example.org.
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with its
prestigious scientific collaborators, has diagnostic programs in gynecologic
oncology and women's health.
The company's lead diagnostic, OVA1®, is a blood test for pre-surgical
assessment of ovarian tumors for malignancy, using an innovative algorithmic
approach. As the first FDA-cleared, protein-based In Vitro Diagnostic
Multivariate Index Assay, OVA1 represents a new class of software-based
diagnostics. For additional information, including published clinical trials,
Investor Relations Contact:
Liolios Group, Inc.
SOURCE Vermillion, Inc.
Press spacebar to pause and continue. Press esc to stop.